Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2015 Dec 23

PMID 26692394

Citations 3

Authors

Rose I Okonkwo

Anita E Weidmann

Emmanuel E Effa

Affiliations

Soon will be listed here.

Abstract

Introduction: Tenofovir disoproxil fumarate (TDF)-containing regimens in the treatment of HIV-infected children have safety concerns with respect to renal and bone toxicity.

Objective: The aim of this study was to systematically review and critically appraise the literature relating to the reported renal and bone adverse effects of TDF-based regimens in the treatment of HIV-infected children from 2 to 19 years old.

Methods: Searches were performed using the Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing and Allied Health Literature (CINAHL), MEDLINE, OvidSP, ScienceDirect and Web of Science databases and platforms. All primary studies involving tenofovir use in HIV-infected children were sought. Studies that involved the use of TDF for pre- and post-exposure prophylaxis, and treatment of chronic hepatitis B virus infection were excluded. Data on study characteristics, participant's characteristics, therapeutic intervention and adverse effects were extracted using a piloted tool. In addition, pharmacovigilance data from the WHO Adverse Reaction database were included.

Results: We identified 19 studies that reported the presence of renal and bone adverse effects of TDF and these included a total of 1100 study participants. The reports were in distinctly heterogeneous participant groups. A total of 287 renal and bone adverse effects were reported (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 participants stopped their TDF-containing regimen due to these adverse effects. In addition, the pharmacovigilance data from the WHO Adverse Reaction database reported 101 renal and bone adverse effects for patients whose indication was HIV/AIDS.

Conclusion: This systematic review summarises the reports of renal and bone adverse effects of a TDF-containing regimen in the treatment of HIV-infected children. Our findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.

Citing Articles

Safety and efficacy of abacavir for treating infants, children, and adolescents living with HIV: a systematic review and meta-analysis.

Jesson J, Saint-Lary L, Revegue M, ORourke J, Townsend C, Renaud F Lancet Child Adolesc Health. 2022; 6(10):692-704.

PMID: 36058225 PMC: 9474298. DOI: 10.1016/S2352-4642(22)00213-9.

Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications.

Trougakos I, Stamatelopoulos K, Terpos E, Tsitsilonis O, Aivalioti E, Paraskevis D J Biomed Sci. 2021; 28(1):9.

PMID: 33435929 PMC: 7801873. DOI: 10.1186/s12929-020-00703-5.

Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children.

Lal B, Sood V, Khanna R, Rawat D, Verma S, Alam S Indian J Gastroenterol. 2018; 37(4):326-334.

PMID: 30168073 DOI: 10.1007/s12664-018-0878-1.

References

Sackett D, WENNBERG J . Choosing the best research design for each question. BMJ. 1998; 315(7123):1636. PMC: 2128012. DOI: 10.1136/bmj.315.7123.1636. View

Purdy J, Gafni R, Reynolds J, Zeichner S, Hazra R . Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008; 152(4):582-4. PMC: 2390888. DOI: 10.1016/j.jpeds.2007.12.020. View

Gracey D, Fernando M, Ziegler J, White C, Post J . An unrecognised case of tenofovir-associated Fanconi syndrome. Med J Aust. 2012; 196:111-2. DOI: 10.5694/mja11.11122. View

Pontrelli G, Cotugno N, Amodio D, Zangari P, Tchidjou H, Baldassari S . Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. BMC Infect Dis. 2012; 12:18. PMC: 3306735. DOI: 10.1186/1471-2334-12-18. View

Wood S, Shah S, Steenhoff A, Meyers K, Kaplan B, Rutstein R . Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDS. 2009; 23(1):1-4. DOI: 10.1089/apc.2008.0106. View

Pozniak A . Tenofovir: what have over 1 million years of patient experience taught us?. Int J Clin Pract. 2008; 62(8):1285-93. DOI: 10.1111/j.1742-1241.2008.01817.x. View

Cooper R, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M . Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010; 51(5):496-505. DOI: 10.1086/655681. View

Bunders M, Frinking O, Scherpbier H, van Arnhem L, van Eck-Smit B, Kuijpers T . Bone mineral density increases in HIV-infected children treated with long-term combination antiretroviral therapy. Clin Infect Dis. 2012; 56(4):583-6. DOI: 10.1093/cid/cis917. View

Vigano A, Aldrovandi G, Giacomet V, Merlo M, Martelli L, Beretta S . Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2006; 10(8):917-24. View

10.

Rosso R, Parodi A, Torrisi C, Terlizzi F, Viscoli C, Vignolo M . A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: a report from 5 years of clinical experience. AIDS Res Hum Retroviruses. 2010; 26(12):1265-6. DOI: 10.1089/aid.2010.0122. View

11.

Vigano A, Bedogni G, Manfredini V, Giacomet V, Cerini C, Di Nello F . Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Investig. 2011; 31(6):407-15. DOI: 10.2165/11590400-000000000-00000. View

12.

Riordan A, Judd A, Boyd K, Cliff D, Doerholt K, Lyall H . Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland. Pediatr Infect Dis J. 2009; 28(3):204-9. DOI: 10.1097/INF.0b013e31818c8d2c. View

13.

Aurpibul L, Puthanakit T . Review of tenofovir use in HIV-infected children. Pediatr Infect Dis J. 2014; 34(4):383-91. DOI: 10.1097/INF.0000000000000571. View

14.

Negra M, Carvalho A, Zilda de Aquino M, da Silva M, Pinto J, White K . A randomized study of tenofovir disoproxil fumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012; 31(5):469-73. DOI: 10.1097/INF.0b013e31824bf239. View

15.

Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A . Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004; 89(1):24-8. DOI: 10.1210/jc.2003-030767. View

16.

Gafni R, Hazra R, Reynolds J, Maldarelli F, Tullio A, DeCarlo E . Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006; 118(3):e711-8. DOI: 10.1542/peds.2005-2525. View

17.

Hall A . Update on tenofovir toxicity in the kidney. Pediatr Nephrol. 2012; 28(7):1011-23. DOI: 10.1007/s00467-012-2269-7. View

18.

Golder S, McIntosh H, Duffy S, Glanville J . Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. Health Info Libr J. 2006; 23(1):3-12. DOI: 10.1111/j.1471-1842.2006.00634.x. View

19.

Purswani M, Patel K, Kopp J, Seage 3rd G, Chernoff M, Hazra R . Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2012; 32(5):495-500. PMC: 3800277. DOI: 10.1097/INF.0b013e31827f4eff. View

20.

Hazra R, Gafni R, Maldarelli F, Balis F, Tullio A, DeCarlo E . Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005; 116(6):e846-54. DOI: 10.1542/peds.2005-0975. View